DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Bodal Chemicals Limited — Board Meeting Intimation

NSE 1 hr ago·26 Oct 2026, 6:17 am

Bodal Chemicals

Bodal Chemicals has announced that its board will meet on November 3, 2026, to review and approve the company's unaudited quarterly financial results for the period ending September 2026. This is a routine corporate governance procedure where the board reviews the company's performance before the results are officially disclosed to the public.

This announcement is primarily a procedural update for investors, as it confirms the timeline for the release of the company's financial performance. It signals that the results are nearing completion and will soon be available for public review.

Investors should watch for the actual release of the financial results to assess the company's operational performance and financial health. The market will likely react to the numbers, including revenue growth, profit margins, and any commentary from the management regarding future outlook.